908 Devices/$MASS
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About 908 Devices
908 Devices Inc develops a suite of purpose-built handheld devices for point-of-need chemical analysis. Leveraging mass spectrometry, optical spectroscopy, analytics and machine learning technologies, the company makes devices that are smaller and more accessible than conventional laboratory instruments. Its devices, including MX908, ThreatID, XplorIR and VipIR, are used to analyze unknown materials and provide actionable answers in health, safety and defense technology applications, addressing the fentanyl and illicit drug crisis, toxic carcinogen exposure and security threats. The company reimagines mass spectrometry technology by developing smaller, lower-cost and simpler-to-operate devices compared to conventional instruments, and generates maximum revenue from the United States.
- Ticker
- $MASS
- Sector
- Digital Hardware
- Primary listing
- NASDAQ
- Employees
- 172
- Headquarters
- Burlington, United States
- Website
- 908devices.com
908 Devices Metrics
BasicAdvanced
$420M
-
-$0.94
0.63
-
Price and volume
Market cap
$420M
Beta
0.63
52-week high
$13.35
52-week low
$5.03
Average daily volume
374K
Financial strength
Current ratio
2.671
Quick ratio
2.291
Long term debt to equity
0.028
Total debt to equity
0.034
Profitability
EBITDA (TTM)
-16.832
Gross margin (TTM)
52.65%
Net profit margin (TTM)
-56.96%
Operating margin (TTM)
-34.84%
Effective tax rate (TTM)
0.55%
Revenue per employee (TTM)
$350,000
Management effectiveness
Return on assets (TTM)
-6.92%
Return on equity (TTM)
-24.95%
Valuation
Price to revenue (TTM)
6.126
Price to book
3.05
Price to tangible book (TTM)
5.47
Price to free cash flow (TTM)
606.043
Free cash flow yield (TTM)
0.17%
Free cash flow per share (TTM)
0.017
Growth
Revenue change (TTM)
13.35%
Earnings per share change (TTM)
80.13%
3-year revenue growth (CAGR)
7.47%
3-year earnings per share growth (CAGR)
-7.43%
What the Analysts think about 908 Devices
Analyst ratings (Buy, Hold, Sell) for 908 Devices stock.
Analyst projections of the future price of 908 Devices stock.
Bulls say / Bears say
Second-quarter revenue rose 23%, and 908 Devices raised the low end of its 2026 revenue outlook to $68 million, implying 21%–25% annual growth. The adjusted EBITDA loss more than halved year on year, showing progress towards better operating leverage. (908 Devices)
Demand is growing across newer handheld products: VipIR passed 100 units shipped since launch, while XplorIR placements rose nearly 70% over the year to June. A subsequent $6 million ProtectIR order adds a sizeable near-term revenue opportunity. (908 Devices, The Motley Fool)
The NIRLab acquisition adds a lower-cost drug-screening product with multi-year software subscriptions. In its first 60 days after the deal closed, 908 Devices sold more than 35 units, an early sign that the expanded offering may broaden adoption and recurring income. (The Motley Fool)
The company remains loss-making: it reported a $23.8 million net loss from continuing operations in the first half of 2026 and says it expects further operating losses. Continued cash consumption could eventually increase the need for external funding and expose shareholders to dilution. (SEC)
Sales rely heavily on government buyers, where procurement can take time and depend on budget cycles; the company warns that orders and revenue can vary significantly between periods and may be concentrated among a few customers. The delayed AVCAD programme was excluded from 2026 guidance, leaving that potential upside uncertain. (SEC, The Motley Fool)
Recurring revenue is not yet keeping pace with device sales: it fell to 30% of first-half revenue from 36% a year earlier. Service revenue also declined, partly because a US defence customer paused coverage for MX908 devices, which weakens revenue visibility. (SEC)
Data summarised monthly by Lightyear AI. Last updated on 1 Nov 2026.
908 Devices Financial Performance
Revenues and expenses
908 Devices Earnings Performance
Company profitability
Upcoming events
No upcoming events
908 Devices News
AllArticlesVideos
Funds containing 908 Devices
Fund name | Fund size | $MASS weighting |
|---|---|---|
ARK Genomic Revolution€AAKG | $123M | 1.16% |
ARK Genomic Revolution£ARCG | $123M | 1.16% |
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.01% |
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.